MARKET

INKT

INKT

Mink Therapeutics, Inc.
NASDAQ
11.27
+0.27
+2.45%
After Hours: 11.27 0 0.00% 19:34 08/14 EDT
OPEN
11.10
PREV CLOSE
11.00
HIGH
11.50
LOW
10.95
VOLUME
6.79K
TURNOVER
--
52 WEEK HIGH
18.17
52 WEEK LOW
8.48
MARKET CAP
56.15M
P/E (TTM)
-3.9671
1D
5D
1M
3M
1Y
5Y
1D
Analyst Maintains Buy on MiNK Therapeutics, Reiterates $35 Price Target on Promising Early Data for agenT-797
TipRanks · 1d ago
MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript
Benzinga · 2d ago
MiNK Therapeutics GAAP EPS of -$0.62 misses by $0.02
Seeking Alpha · 2d ago
*MiNK Therapeutics Reports Observations From Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
Dow Jones · 2d ago
MiNK Therapeutics Q2 EPS $(0.62) Misses $(0.60) Estimate
Benzinga · 2d ago
Press Release: MiNK Therapeutics Reports Second -2-
Dow Jones · 2d ago
Press Release: MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
Dow Jones · 2d ago
Weekly Report: what happened at INKT last week (0803-0807)?
Weekly Report · 5d ago
More
About INKT
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.

Webull offers Mink Therapeutics Inc stock information, including NASDAQ: INKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INKT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INKT stock methods without spending real money on the virtual paper trading platform.